Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
- Author:
Eun Kyoung LEE
1
;
Sooyoung KIM
;
Eunhee SOHN
Author Information
- Publication Type:Review Article
- From:Journal of the Korean Neurological Association 2025;43(2):83-89
- CountryRepublic of Korea
- Language:Korean
- Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic autoimmune disease of the peripheral nervous system, primarily treated with corticosteroids and intravenous immunoglobulin as first-line therapies. Early treatment yields better outcome before nerve damage caused by the immune response. Once axonal damage has progressed, immunotherapy becomes ineffective, making early intervention crucial. Additionally, as treatment responses vary among patients, it is essential to assess treatment efficacy objectively and tailor therapy accordingly. Since there are currently no biomarkers that accurately reflect disease status, regular physical examinations are necessary to evaluate treatment effectiveness and adjust maintenance therapy. This review outlines the current clinical guidelines for the treatment of CIDP and explores emerging therapeutic options, including neonatal Fc receptor inhibitors and complement pathway inhibitors.
